# A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

> **NCT03964415** · PHASE3 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 3900 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV
- **BIOLOGICAL:** Clade C and Mosaic gp140 HIV bivalent vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03964415
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-31
- **Primary completion:** 2023-08-10
- **Final completion:** 2023-08-10
- **Target enrollment:** 3900 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964415, "A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03964415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*